CB
CYNTHIA BENS
PERSONALIZED MEDICINE COALITION · Washington, DC · registered since 2024
Registered · LDAActive
At a glance
Registered since
2024
Senate LDA system
Clients
1
last 3 years
Filings
3
5 agencies contacted
Activity
filings by quarter
Works on
Background
Government experience
Staff
Representative Paul E. Kanjorski
Disclosed on LD-2 filings
Career
PM
Specific issues
Congressional Personalized Medicine Caucus Precision Medicine Answers for Kids Today Act and Medicaid Early Periodic Screening, Diagnostic and Treatment Benefit 21st Century Cures 2.0 Initiative Response to House Request for Information American Privacy Rights Act provisions related to personalized medicine Oversight of Laboratory Developed Tests H.R. 5539/S. 3131 Optimizing Research Progress Hope And New (ORPHAN) Cures Act H.R. 5547/S.476 Maintaining Investments in New Innovation (MINI) Act H.R. 7174 Ensuring Pathways to Innovative Cures (EPIC) Act H.R. 8267 Old Drugs, New Cures Act H.R. 2407 Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act CMS Implementation of Medicare Drug Price Negotiation Program/ Medicare Drug Price Negotiation Program: Draft Guidance, Implementation of Sections 1191 - 1198 of the Social Security Act for Initial Price Applicability Year 2027 and Manufacturer Effectuation of the Maximum Fair Price in 2026 and 2027 Medicare and Medicaid Programs: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; etc (CMS-1809P) Medicare and Medicaid Programs; CY 2025 Payment Policies under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; etc (CMS-1807-P) Agency for Healthcare Research and Qualitys (AHRQs) Review Protocol titled: Blood-based Tests for Multiple Cancer Screening: A Systematic Review Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies [Docket No. FDA-2021-D0789] Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community
FY 2025 Food and Drug Administration Budget Priorities for CDER, CBER and CDRH FY 2025 National Institutes of Health Budget Priorities
Congressional Personalized Medicine Caucus Precision Medicine Answers for Kids Today Act/Ending the Diagnostic Odyssey Act Seniors Timely Access to Care Act FDA Rulemaking on Laboratory Developed Tests Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community CMS Implementation of Medicare Drug Price Negotiation Program CMS Final Rule Misclassification of Drugs, Program Administration and Program Integrity Updates under the Medicaid Drug Rebate Program (MDRP) CMS Inpatient Prospective Payment System (IPPS) reimbursement for low-volume rare disease treatments and CAR T Cell Therapies
Congressional Personalized Medicine Caucus Precision Medicine Answers for Kids Today Act/Ending the Diagnostic Odyssey Act Right Drug Dose Now Act FDA Proposed Rulemaking on Laboratory Developed Tests Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community CMS Implementation of Medicare Drug Price Negotiation Program CMS Medicare Administrative Contractors Novitas and FCSO proposed Local Coverage Determination (LCD) related to genetic testing for oncology CMS Inpatient Prospective Payment System (IPPS) reimbursement for low-volume rare disease treatments
FY 2024 Food and Drug Administration Budget Priorities for CDER, CBER and CDRH FY 2024 National Institutes of Health Budget Priorities